UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Atezolizumab for First-Line Treatment of PD-L1–Selected Patients with NSCLC

The New England journal of medicine, 2020-10, Vol.383 (14), p.1328-1339

2020

Volltextzugriff (PDF)

Updated Overall Survival Analysis From IMpower110: Atezolizumab Versus Platinum-Based Chemotherapy in Treatment-Naive Programmed Death-Ligand 1–Selected NSCLC

Journal of thoracic oncology, 2021-11, Vol.16 (11), p.1872-1882

2021

Volltextzugriff (PDF)

Myelopreservation with Trilaciclib in Patients Receiving Topotecan for Small Cell Lung Cancer: Results from a Randomized, Double-Blind, Placebo-Controlled Phase II Study

Advances in therapy, 2021-01, Vol.38 (1), p.350-365

2021

Volltextzugriff (PDF)

Overweight and obesity in polycystic ovary syndrome: association with inflammation, oxidative stress and dyslipidaemia

British journal of nutrition, 2022-08, Vol.128 (4), p.604-612

2022

Volltextzugriff (PDF)

RESILIENT Part 2: A Randomized, Open-Label Phase III Study of Liposomal Irinotecan Versus Topotecan in Adults With Relapsed Small Cell Lung Cancer

Journal of clinical oncology, 2024-07, Vol.42 (19), p.2317-2326

2024

Volltextzugriff (PDF)

Predictors of Subclinical Cardiovascular Disease in Women with Polycystic Ovary Syndrome: Interrelationship of Dyslipidemia and Arterial Blood Pressure

International Journal of Endocrinology, 2015-01, Vol.2015, p.812610-9

2015

Volltextzugriff (PDF)

607 TTFields therapy with an immune checkpoint inhibitor in metastatic non-small cell lung cancer (mNSCLC) with progression on/after platinum-based therapy: histology subgroups in the pivotal LUNAR study

Journal for immunotherapy of cancer, 2023-11, Vol.11 (Suppl 1), p.A691-A691

2023

Volltextzugriff (PDF)

Mobile phone use while driving-literary review

Transportation research. Part F, Traffic psychology and behaviour, 2017-05, Vol.47, p.132-142

2017

Volltextzugriff (PDF)

Avelumab in Combination With Cetuximab and Chemotherapy as First-Line Treatment for Patients With Advanced Squamous NSCLC

JTO clinical and research reports, 2023-02, Vol.4 (2), p.100461-100461, Article 100461

2023

Volltextzugriff (PDF)

Polycystic Ovary Syndrome: A Contemporary Clinical Approach

Current pharmaceutical design, 2021-01, Vol.27 (36), p.3812-3820

2021

Volltextzugriff (PDF)

Trilaciclib prior to gemcitabine plus carboplatin for metastatic triple-negative breast cancer: phase III PRESERVE 2

Future oncology (London, England), 2022-10, Vol.18 (33), p.3701-3711

2022

Volltextzugriff (PDF)

Nonalcoholic Fatty Liver Disease in Patients with Polycystic Ovary Syndrome

Current pharmaceutical design, 2018-01, Vol.24 (38), p.4593-4597

2018

Volltextzugriff (PDF)

Hypertension in Polycystic Ovary Syndrome: Novel Insights

Current hypertension reviews, 2020-01, Vol.16 (1), p.55-60

2020

Volltextzugriff (PDF)

Effects of Trilaciclib on Chemotherapy-Induced Myelosuppression and Patient-Reported Outcomes in Patients with Extensive-Stage Small Cell Lung Cancer: Pooled Results from Three Phase II Randomized, Double-Blind, Placebo-Controlled Studies

Clinical lung cancer, 2021-09, Vol.22 (5), p.449-460

2021

Volltextzugriff (PDF)

HERIZON: A phase 2 study of HER-Vaxx (IMU-131), a HER2-targeting peptide vaccine, plus standard of care chemotherapy in patients with HER2-overexpressing metastatic or advanced gastric/GEJ adenocarcinoma— Overall survival analysis

Journal of clinical oncology, 2023-02, Vol.41 (4_suppl), p.289-289

2023

Volltextzugriff (PDF)

Evaluation of a Summary Score for Dyslipidemia, Oxidative Stress and Inflammation (The Doi Score) in Women with Polycystic Ovary Syndrome and its Relationship with Obesity

Journal of medical biochemistry, 2018-12, Vol.37 (4), p.476-485

2018

Volltextzugriff (PDF)

Lipid accumulation product as a marker of cardiometabolic susceptibility in women with different phenotypes of polycystic ovary syndrome

European journal of endocrinology, 2016-12, Vol.175 (6), p.551-560

2016

Volltextzugriff (PDF)

Myelopreservation and reduced use of supportive care with trilaciclib in patients with small cell lung cancer

Journal of clinical oncology, 2020-05, Vol.38 (15_suppl), p.12096-12096

2020

Volltextzugriff (PDF)

Bevacizumab biosimilar and reference bevacizumab in subjects with stage IIIB/IV no squamous non-small cell lung cancer (NSCLC) (STELLA study): Results for the primary endpoint in a confirmatory, double-blind, randomized, controlled study

Journal of clinical oncology, 2020-05, Vol.38 (15_suppl), p.e21542-e21542

2020

Volltextzugriff (PDF)

Bevacizumab biosimilar (MB02) and reference bevacizumab in patients with stage IIIB/IV non-squamous non-small cell lung cancer (NSCLC) (STELLA study): Multiple Imputation analysis

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.e15003-e15003

2021

Volltextzugriff (PDF)

Abstract P1-17-02: ZN-c5, an oral selective estrogen receptor degrader (SERD), in women with advanced estrogen receptor-positive (ER+)/human epidermal growth factor receptor 2 negative (HER2-) breast cancer

Cancer research (Chicago, Ill.), 2022-02, Vol.82 (4_Supplement), p.P1-P1-17-02

2022

Volltextzugriff (PDF)

Assessment of age-related influences on the quality of life of breast cancer patients before and after surgical treatment

Vojnosanitetski pregled, 2020, Vol.77 (9), p.908-916

2020

Volltextzugriff (PDF)

Five-year survival in patients with extensive-stage small cell lung cancer treated with atezolizumab in the Phase III IMpower133 study and the Phase III IMbrella a extension study

Lung cancer (Amsterdam, Netherlands), 2024-08, p.107924, Article 107924

2024

Volltextzugriff (PDF)

1 – 25 von 102

Suche als RSS-Feed

Aktive Filter

KollektionNexis

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(84)
Mit Volltextzugriff
(82)

Publikationsform

Sprache

2 weitere anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(4)

Menü

Weitere Dienste

Einstellungen

Atezolizumab for First-Line Treatment of PD-L1–Selected Patients with NSCLC

Updated Overall Survival Analysis From IMpower110: Atezolizumab Versus Platinum-Based Chemotherapy in Treatment-Naive Programmed Death-Ligand 1–Selected NSCLC

Myelopreservation with Trilaciclib in Patients Receiving Topotecan for Small Cell Lung Cancer: Results from a Randomized, Double-Blind, Placebo-Controlled Phase II Study

Overweight and obesity in polycystic ovary syndrome: association with inflammation, oxidative stress and dyslipidaemia

RESILIENT Part 2: A Randomized, Open-Label Phase III Study of Liposomal Irinotecan Versus Topotecan in Adults With Relapsed Small Cell Lung Cancer

Predictors of Subclinical Cardiovascular Disease in Women with Polycystic Ovary Syndrome: Interrelationship of Dyslipidemia and Arterial Blood Pressure

607 TTFields therapy with an immune checkpoint inhibitor in metastatic non-small cell lung cancer (mNSCLC) with progression on/after platinum-based therapy: histology subgroups in the pivotal LUNAR study

Mobile phone use while driving-literary review

Avelumab in Combination With Cetuximab and Chemotherapy as First-Line Treatment for Patients With Advanced Squamous NSCLC

Polycystic Ovary Syndrome: A Contemporary Clinical Approach

Trilaciclib prior to gemcitabine plus carboplatin for metastatic triple-negative breast cancer: phase III PRESERVE 2

Nonalcoholic Fatty Liver Disease in Patients with Polycystic Ovary Syndrome

Hypertension in Polycystic Ovary Syndrome: Novel Insights

Atezolizumab versus chemotherapy in advanced or metastatic NSCLC with high blood-based tumor mutational burden: primary analysis of BFAST cohort C randomized phase 3 trial

Tumor Treating Fields therapy with standard systemic therapy versus standard systemic therapy alone in metastatic non-small-cell lung cancer following progression on or after platinum-based therapy (LUNAR): a randomised, open-label, pivotal phase 3 study

Effects of Trilaciclib on Chemotherapy-Induced Myelosuppression and Patient-Reported Outcomes in Patients with Extensive-Stage Small Cell Lung Cancer: Pooled Results from Three Phase II Randomized, Double-Blind, Placebo-Controlled Studies

HERIZON: A phase 2 study of HER-Vaxx (IMU-131), a HER2-targeting peptide vaccine, plus standard of care chemotherapy in patients with HER2-overexpressing metastatic or advanced gastric/GEJ adenocarcinoma— Overall survival analysis

Evaluation of a Summary Score for Dyslipidemia, Oxidative Stress and Inflammation (The Doi Score) in Women with Polycystic Ovary Syndrome and its Relationship with Obesity

Lipid accumulation product as a marker of cardiometabolic susceptibility in women with different phenotypes of polycystic ovary syndrome

Myelopreservation and reduced use of supportive care with trilaciclib in patients with small cell lung cancer

Bevacizumab biosimilar and reference bevacizumab in subjects with stage IIIB/IV no squamous non-small cell lung cancer (NSCLC) (STELLA study): Results for the primary endpoint in a confirmatory, double-blind, randomized, controlled study

Bevacizumab biosimilar (MB02) and reference bevacizumab in patients with stage IIIB/IV non-squamous non-small cell lung cancer (NSCLC) (STELLA study): Multiple Imputation analysis

Abstract P1-17-02: ZN-c5, an oral selective estrogen receptor degrader (SERD), in women with advanced estrogen receptor-positive (ER+)/human epidermal growth factor receptor 2 negative (HER2-) breast cancer

Assessment of age-related influences on the quality of life of breast cancer patients before and after surgical treatment

Five-year survival in patients with extensive-stage small cell lung cancer treated with atezolizumab in the Phase III IMpower133 study and the Phase III IMbrella a extension study

Aktive Filter

Suchergebnisse filtern